Investigational drug · Phase 2
BL-M09D1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Gynecological Malignancies, Urothelial Carcinoma (UC).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "BL-M09D1"
First trial start
2026
Aug 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BL-M09D1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumors
- Gynecological Malignancies
- Urothelial Carcinoma (UC)
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BL-M09D1" as an intervention, largest first.
- A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid TumorsNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07769229 · 126 participants (planned) · Start Aug 2026 · Primary completion Dec 2028
Drug: BL-M09D1 · For: Gynecological Malignancies; Solid Tumors
Sites: Fuzhou, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06954077 · 45 participants (planned) · Start May 15, 2025 · Primary completion May 2027
Drug: BL-M09D1 · For: Gastrointestinal Tumor; Solid Tumor
Sites: Guangzhou, China
- A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07837622 · 42 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M09D1 · For: Urothelial Carcinoma (UC); Solid Tumors
Sites: Guangzhou, China
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07056556 · 31 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 2027
Drug: BL-M09D1 · For: Non-small Cell Lung Cancer; Solid Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumors
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- DB-1311BNT324Phase 34 trials
BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.